Deep search
Profile Picture
  • All
  • Search
  • Images
  • Videos
  • Maps
  • News
  • Copilot
  • More
    • Shopping
    • Flights
    • Travel
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • Politics
Order byBest matchMost fresh
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days

News

Wegovy, FDA and MASH

Digest more
Fierce Pharma · 5h
Novo's Wegovy picks up 3rd indication with key FDA approval in the liver disease MASH
With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug approved in a severe form of fatty liver disease. | The FDA has signed off on an accelerated approval for Novo Nordisk's Wegovy to treat certain adults with metabolic-associated steatohepatitis.

Continue reading

 · 5h
Novo’s Wegovy becomes first GLP-1 drug approved for MASH
Managed Healthcare Executive · 6h
FDA Grants Accelerated Approval of Wegovy to Treat Liver Disease
2h

A Common Weight Loss Drug Can Treat Severe Liver Disease, F.D.A. Says

The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on ...
Medscape
8h

Wegovy Approved for MASH With Fibrosis, No Cirrhosis

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...
MedPage Today
1h

Semaglutide Gets FDA Greenlight for MASH

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...
Zacks Investment Research on MSN3h

NVO Stock Up on FDA Nod for Wegovy in MASH: More Upside Ahead?

Novo Nordisk NVO announced that the FDA has granted accelerated approval to its blockbuster GLP-1 drug, Wegovy (semaglutide 2 ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results
Feedback
© 2025 Microsoft
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices
  • Consumer Health Privacy